Prostate cancer imaging

Picchio, Maria; Piert, Morand

doi:10.1007/s00259-013-2444-5

Cited by 6 publications

(8 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The previous literature reported that an Al 18 F chelate BBN peptide complex, 18 F‐Al‐NOTA‐8‐Aoc‐BBNNH 2 , had a moderate uptake in the PC‐3 tumor (~2% ID/g i.v. 1 h p.i.…”

Section: Discussionmentioning

confidence: 99%

“…Radiolabeling BBN analogs with 18 F often involves a time‐consuming customized process. A novel method to label peptides with Al 18 F complex has been applied for labeling the bombesin agonist, NOTA‐8‐Aoc‐BBN NH2 . Recent studies showed that GRPR antagonists may be superior to agonist for tumor imaging with favorable in vivo characteristics .…”

Section: Discussionmentioning

confidence: 99%

“…and good pharmacokinetic properties with clean abdomen imaging. The altered in vivo kinetics may be mainly attributed to the higher hydrophilicity of 18 F‐Al‐NOTA‐MATBBN than 18 F‐Al‐NOTA‐8‐Aoc‐BBNNH 2 since the octanol–water partition coefficients were −2.40 ± 0.07 and −1.47 ± 0.05, respectively. MicroPET images also clearly demonstrate specific tumor uptake of the 18 F‐Al‐NOTA‐MATBBN at 1 h when compared with animals also given blocking peptide.…”

Section: Discussionmentioning

confidence: 99%

“…Detection of prostate cancer with the most widely used PET tracer, 18 F-FDG, is challenging since glucose utilization in prostate carcinoma cells is not enhanced significantly compared with that of normal cells. Other tracers, such as 18 F-or 11 C-choline and 11 C-acetate, etc., have shown promise for prostate cancer imaging; however, the diagnostic accuracy of these imaging agents is limited because most prostate tumor lesions are characterized by low metabolic activities (7,(9)(10)(11).…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

PET imaging of prostate tumors with ¹⁸F‐Al‐NOTA‐MATBBN

Pan

Yan

Yang

et al. 2014

Contrast Media & Molecular

View full text Add to dashboard Cite

Overexpression of the gastrin-releasing peptide receptor (GRPR) in prostate cancer provides a promising target for detection the disease. MATBBN is a new bombesin analog originating from the GRPR antagonists with a hydrophilic linker. In this study NOTA-conjugated MATBBN was labeled by the Al(18)F method and the potential of (18)F-Al-NOTA-MATBBN for prostate tumor PET imaging was also evaluated. NOTA-MATBBN was radiolabeled with (18) F using Al(18)F complexes. Partition coefficient, in vitro stability and GRPR binding affinity were also determined. PET studies were performed with (18)F-Al-NOTA-MATBBN in PC-3 tumor-bearing mice. (18)F-Al-NOTA-MATBBN can be produced within 30 min with a decay-corrected yield of 62.5 ± 2.1% and a radiochemical purity of >98%. The logP octanol-water value for the Al(18)F-labeled BBN analog was -2.40 ± 0.07 and the radiotracer was stable in phosphate-buffered saline and human serum for 2 h. The IC50 values of displacement for the (18)F-Al-NOTA-MATBBN with MATBBN was 126.9 ± 2.75 nm. The PC-3 tumors were clearly visible with high contrast after injection of the labeled peptide. At 60 min post-injection, the tumor uptakes for (18)F-Al-NOTA-MATBBN and (18)F-FDG were 4.59 ± 0.43 and 1.98 ± 0.35% injected dose/g, and tumor to muscle uptake radios for two tracers were 6.77 ± 1.10 and 1.78 ± 0.32, respectively. Dynamic PET revealed that (18) F-Al-NOTA-MATBBN was excreted mainly through the kidneys. GRPR-binding specificity was also demonstrated by reduced tumor uptake of (18)F-Al-NOTA-MATBBN after coinjection with excess unlabeled MATBBN peptide at 1 h post-injection. NOTA- MATBBN could be labeled rapidly with (18)F using one step method. (18)F-Al-NOTA-MATBBN may be a promising PET imaging agent for prostate cancer.

show abstract

“…The previous literature reported that an Al 18 F chelate BBN peptide complex, 18 F‐Al‐NOTA‐8‐Aoc‐BBNNH 2 , had a moderate uptake in the PC‐3 tumor (~2% ID/g i.v. 1 h p.i.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

PET imaging of prostate tumors with ¹⁸F‐Al‐NOTA‐MATBBN

Pan

Yan

Yang

et al. 2014

Contrast Media & Molecular

View full text Add to dashboard Cite

show abstract

“…34,35 Due to the di±culty for PET radiotracers to target prostate cancer, PET/CT also has limited sensitivity for prostate cancer detection. 36 In this review, we introduce an emerging imaging modality, photoacoustic imaging (PAI), as a potential tool for the detection of prostate cancer. The review includes: (a) principals of PAI; (b) PAI systems for prostate imaging; (c) PAI of prostate cancer using endogenous contrast; (d) PAI of prostate cancer using exogenous contrast agents, and (e) future outlook.…”

mentioning

confidence: 99%

Photoacoustic imaging of prostate cancer

Yang

Xiang

2017

J. Innov. Opt. Health Sci.

View full text Add to dashboard Cite

Photoacoustic imaging (PAI), also known as optoacoustic imaging, is a rapidly growing imaging modality with potential in medical diagnosis and therapy monitoring. This paper focuses on the techniques of prostate PAI and its potential applications in prostate cancer detection. Transurethral light delivery combined with transrectal ultrasound detection overcomes light scattering in the surrounding tissue and provides optimal photoacoustic signals while minimizing invasiveness. While label-free PAI based on endogenous contrast has promising potential for prostate cancer detection, exogenous contrast agents can further enhance the sensitivity and speci¯city of prostate cancer PAI. Further in vivo studies are required in order to achieve the translation of prostate PAI to clinical implementation. The minimal invasiveness, relatively low cost, high speci¯city and sensitivity, and real-time imaging capability are valuable advantages of PAI that may improve the current prostate cancer management in clinic.

show abstract